Literature DB >> 2507578

Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis.

M Berger1, R U Sorensen, M F Tosi, D G Dearborn, G Döring.   

Abstract

Activation of human neutrophils (PMN) is accompanied by rapid upregulation of CR1, the C3b receptor, and CR3, the iC3b receptor, which also serves as the PMN's major adherence protein. This is necessary for migration and phagocytosis, but the extent of expression of these proteins on PMN at inflammatory sites has not been determined. We used monoclonal antibodies and flow cytometry to assess CR1 and CR3 expression on PMN in bronchoalveolar lavage (BAL) fluid of cystic fibrosis (CF) patients chronically infected with pseudomonas and in sterile joint fluid of arthritis patients. Resting peripheral blood PMN from these patients and normals expressed similar low levels of CR1 and CR3, and the patients' PMN increased CR1 and CR3 expression normally when stimulated in vitro. CR3 expression on CF BAL PMN was 90 +/- 12% of that on the same patient's blood cells stimulated in vitro with FMLP. In contrast, CR1 expression on BAL PMN was only 27 +/- 8% of that on stimulated blood cells. Similar results were obtained for joint PMN. This pattern could be reproduced in vitro by treating FMLP-stimulated blood cells with BAL supernatants or with pseudomonas or PMN elastase. The serine protease inhibitors, PMSF and alpha 1-antitrypsin prevented the lavage supernatant from reducing CR1 expression, while metalloprotease inhibitors had no effect. Treatment of PMN with elastase in vitro decrease their ability to kill opsonized Pseudomonas aeruginosa. These results suggest that PMN at inflammatory sites have maximally upregulated expression of their complement receptors, but that CR1 is then cleaved by proteolysis in situ. Although not related to the basic defect in CF, this may interfere with efficient phagocytosis and contribute to the CF patient's inability to eradicate chronic lung infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507578      PMCID: PMC329791          DOI: 10.1172/JCI114298

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  A new method of preparation of pyocyanin and demonstration of an unusual bacterial sensitivity.

Authors:  M Knight; P E Hartman; Z Hartman; V M Young
Journal:  Anal Biochem       Date:  1979-05       Impact factor: 3.365

2.  Microbial elastases. A comparative study.

Authors:  I MANDL; S KELLER; B COHEN
Journal:  Proc Soc Exp Biol Med       Date:  1962-04

3.  A rapid procedure for the large scale purification of elastase and cathepsin G from human sputum.

Authors:  R R Martodam; R J Baugh; D Y Twumasi; I E Liener
Journal:  Prep Biochem       Date:  1979

4.  Leucoattractants enhance complement receptors on human phagocytic cells.

Authors:  A B Kay; E J Glass; D M Salter
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

5.  Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

6.  Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages.

Authors:  M J Thomassen; B Boxerbaum; C A Demko; P J Kuchenbrod; D G Dearborn; R E Wood
Journal:  Pediatr Res       Date:  1979-09       Impact factor: 3.756

7.  Opsonic defect in patients with cystic fibrosis of the pancreas.

Authors:  W D Biggar; B Holmes; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1971-08       Impact factor: 11.205

8.  Modulation of surface CD11/CD18 glycoproteins (Mo1, LFA-1, p150,95) by human mononuclear phagocytes.

Authors:  D R Freyer; M L Morganroth; C E Rogers; M A Arnaout; R F Todd
Journal:  Clin Immunol Immunopathol       Date:  1988-02

9.  Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.

Authors:  P R Craddock; J Fehr; A P Dalmasso; K L Brighan; H S Jacob
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  The role of membrane receptors for C3b and C3d in phagocytosis.

Authors:  A G Ehlenberger; V Nussenzweig
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

View more
  43 in total

1.  Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.

Authors:  C M Costello; C M O'Connor; G A Finlay; P Shiels; M X FitzGerald; J P Hayes
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

2.  Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection.

Authors:  H E Feucht; E Felber; M J Gokel; G Hillebrand; U Nattermann; C Brockmeyer; E Held; G Riethmüller; W Land; E Albert
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

Review 3.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 4.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

5.  Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Authors:  Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller
Journal:  Pediatr Pulmonol       Date:  2013-09-09

Review 6.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 7.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

8.  Faster activation of polymorphonuclear neutrophils in resistant mice during early innate response to Pseudomonas aeruginosa lung infection.

Authors:  P Ø Jensen; C Moser; O Kobayashi; H P Hougen; A Kharazmi; N Høiby
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

9.  Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor.

Authors:  N G McElvaney; H Nakamura; P Birrer; C A Hébert; W L Wong; M Alphonso; J B Baker; M A Catalano; R G Crystal
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

10.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.